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Abstract 
 
Objectives To define in patients undergoing surgery for mitral regurgitation 
(MR) the risk of thrombo-embolic complications, particularly ischemic 
stroke (IS) compared to that in the general population. 
Background MR is frequent, occurs mostly in the elderly and guidelines 
recommend surgery in asymptomatic patients but IS risks are unknown. 
Methods In 1344 patients (65±12 years) consecutively operated for MR 
(procedures: 897 valve repair, MRep; 447 valve replacement, 231 
mechanical, MVRm; 216 biological, MVRb), thrombo-embolic 
complications particularly IS (diagnosed by a neurologist) during follow-up 
were assessed early (<30 days), mid-term (30-180 days) and long-term 
(180 days). 
Results IS occurred in 130 patients and IS or transient ischemic attack in 
201. IS rates were 1.9±0.4% and 2.7±0.5%, at 30 and 180 days and 
8.1±0.8% at 5 years.  IS rates were lowest after MRep vs. MVRb and 
MVRm (6.1±0.9, 8±2.1 and 16.1±2.7% at 5 years, p<0.001).  Comparison to 
IS expected rates in the population showed high risk within 30 days of 
surgery (Risk-ratio 41[26-60], p<0.001 but p>0.10 between procedures) and 
moderate risk after 30 days (risk-ratio 1.7 overall, p<0.001; 1.3 for MRep, 
p=0.07; 0.98 for MVRb, p=0.95; 4.8 for MVRm, p<0.001).  Beyond 180 
days, IS risk declined further and was not different from the general 
population for MRep (1.2, p=0.30) and for MVRb (0.9, p=0.72).  Risk of IS 
or transient ischemic attack was higher than the general population in all 
groups up to 180 days.  The risk of bleeding beyond 30 days was lowest in 
MRep vs. MVRb and MVRm (7±1, 14±4 and 16±3% at 10 years, p<0.001). 
Conclusion Thrombo-embolic complications after MR surgery are both 
reason for concern and encouragement. IS risk is notable early, irrespective 
of the procedure performed, but long-term is not higher than in the general 
population after MRep and MVRb.  Preference for MRep should be 
emphasized and trials aimed at preventing IS should be conducted to reduce 
the thrombo-embolic and hemorrhagic risk in patients undergoing surgery 
for MR.  
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INTRODUCTION 
 
Thromboembolic events (TE) are serious complications that may occur after 
every modality of cardiac surgery.1-3 Most TE are cerebrovascular4 with the 
most serious ischemic stroke (IS) resulting in  poor quality of life and excess 
mortality1, 3, 5, 6. The incidence of IS early after cardiac surgery was reported 
mostly after coronary artery by pass grafting (CABG) surgery between 1 to 
8%1, 5, 7, but is less known after valve surgery8, 9, particularly for mitral 
regurgitation (MR). The issue of TE following MR surgery is of particular 
importance because MR is frequent with aging10 and is the main reason for 
mitral surgery currently, because valve repair (MRep) is the modality of 
choice for surgical treatment of MR so that previous data following valve 
replacement may be changed11 and because surgery has been proposed for 
asymptomatic patients12 in whom any complication represents serious 
concern.  It is thus unclear if TE is related to the type of surgery, if TE risk is 
low with MRep making anticoagulation unnecessary or if surgery multiplies 
the spontaneous risk of stroke13, particularly in elderly patients with MR, a 
fact that may affect the new indications for surgery in such patients. 
Resolving this question is particularly difficult because, with the decrease in 
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rheumatic valve disease14, older patients with MR 10 referred to surgery incur 
spontaneously higher risk of TE and stroke during follow-up. Therefore it is 
essential not only to assess the absolute risk of TE and IS after mitral valve 
(MV)  surgery but also to compare the observed risk with that expected in 
the general population 15. It is also crucial to compare over the early and late 
post-operative period, the TE risk associated with MRep and mitral valve 
replacement (MVR) to determine if the survival advantage associated with 
MRep is additive to lower embolic rates throughout follow up. 
Thus we examined the TE risk associated with various modalities of surgical 
correction of MR, particularly comparing IS risk to that expected in the 
population 
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METHODS 
 
The present study was based on a review of our experience with MRep and 
MVR for the surgical correction of MR. 
 
 
Eligibility Criteria 
Inclusion criteria were organic, ischemic and functional MR as defined by 
echocardiographic and surgical evaluation which underwent repair or 
replacement between January 1, 1980, and December 31, 1995. Patients with 
associated CABG surgery were included in the study. 
Exclusion criteria were presence of mitral stenosis, congenital defects except 
small patent foramen ovale and atrial septal defect, constrictive pericarditis, 
previous mitral valve surgery: plication, valvuloplasty, annuloplasty, valve 
replacement, repair of mitral valve, previous or simultaneous aortic or 
tricuspid valve replacement (tricuspid repair was not an exclusion criteria).  
 
Surgical procedure 
Surgical repair of the mitral valve involved subvalvular (chordal shortening  
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or artificial chord insertion), valvular (mostly resection or plication) and 
annular (mostly ring insertion) intervention. The decision to perform MV 
repair versus replacement was based on the surgeon’s examination of the 
lesions. The lesions repaired compared with those replaced involved MV 
prolapse in 648 versus 208, were ischemic in 148 versus 113, were 
endocarditic in 39 versus 37, were rheumatic in 20 versus 66 and were 
miscellaneous in 42 versus 23.  
The types of prosthesis used in MV replacement were Carpentier-Edwards 
(159), Starr-Edwards (143), St. Jude (59), Ionescu-Shiley (43), Bjork-Shiley 
(27), Hancock (11), Medtronic intact (3) and Hall-Medtronic (2).  
CABG was performed in 338 patients (38%) with MRep, 77 patients (33%) 
with mechanical prosthesis and 92 patients (43%) with biological prosthesis. 
 
Clinical definitions 
Baseline characteristics, cardiovascular history and comorbidity were noted.  
Follow-up events were determined by review of medical records or by 
questionnaires or by telephone calls. Ischemic stroke was defined as the 
persistence for > 24 hours of a focal neurological deficit caused by altered 
circulation of the cerebral hemispheres, brain stem or cerebellum with or 
without computed tomography (CT) or magnetic resonance imaging (MRI) 
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documentation.16 Transient ischemic attack (TIA), was defined as focal 
neurologic event of complete and rapid resolution (<24 hours) related to 
altered circulation of the brain 16 15 17. Peripheral embolic event was defined 
as operative, autopsy, or clinically documented embolus that produces 
symptoms from complete or partial obstruction of a peripheral (non cerebral) 
artery16.  
Bleeding event was defined as any episode of major internal or external 
bleeding that causes death, hospitalization, or permanent injury or 
necessitates transfusion 16. Intracranial hemorrhage (ICH) was assigned only 
after documentation by CT or MRI or autoptic confirmation.  
Atrial fibrillation, paroxysmal or permanent, was considered present if 
recorded on ECG. All the patients of the study were managed with 
contemporary anticoagulation guidelines. 
 
Statistical analysis 
Baseline characteristics are presented as mean ± standard deviation (SD) for 
continuous variables. 
Group comparisons were performed with a standard t test or x2 test when 
appropriate. Event rate estimations were expressed by actuarial analysis and, 
to summarize the incidence of multiple events in individual patients, by 
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yearly linearized rates, expressed in percent per year ± standard error (SE) 
and calculated as the number of events divided by the total patient-years16. 
Observed IS, combined IS/TIA and combined IS/intracranial hemorrhage 
(ICH) rates were compared with expected in the Olmsted County population 
(counted from the Rochester Minnesota Stroke Registry rates) by use of the 
1-sample log-rank test. Expected IS, IS/TIA, combined IS/ICH hazard were 
calculated from incidence rates of IS, combined IS/TIA, combined IS/ICH 
from the Olmsted County population with age and sex similar to those of the 
population of the study. Baseline clinical, operative and echocardiographic 
variables were tested to find possible predictors of IS and bleeding events 
with Cox proportional-hazards modeling and logistic regression analysis was 
used to find predictors of IS and bleeding on the first 30 days after surgery 
and between 30 and 180 days. Variables with P<0.10 by univariate analysis 
were incorporated into multivariate models, and P<0.05 was considered 
significant. 
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RESULTS 
 
 
Study population 
During the study period 1344 patients had MV surgery for MR. The surgical 
procedure performed was MRep in 897 patients (67%), MVRm in 231 
patients (17%) and MVRb in 216 patients (16%). Reoperation was 
performed in 133 patients during the follow-up, 84 after MRep, 20 after 
MVRm and 29 after MVRb. 544 patients were in AF preoperatively and 168 
patients developed AF during the follow up.  
 
Baseline Characteristics 
The preoperative baseline characteristics of the three groups are summarized 
in Table 1. The results show significant differences between the three groups 
regarding clinical, echocardiographic and operative characteristics, mostly 
consistent with a better prognosis in patients with MRep. Instead patients 
who received MVRb were older and more likely to be symptomatic, 
hypertensive and diabetic. 
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Incidence of ischemic stroke after MV surgery   
A total of 130 patients experienced an IS: 65 after MRep, 44 after MVRm 
and 21 in MVRb group. Among them 29 patients suffered a second event, 9 
in MRep group, 19 in MVRm, 1 in MVRb and 13 patients had multiple 
events, 1 in MRep, 11 in MVRm and 1 in MVRb. During the early 
postoperative period (within 30 postoperative days) overall incidence of IS 
was 1.92±0.4%, lower in MRep, 1.47±0.4% and in MVRm, 1.33±0.8% 
compared with MVRb 4.62±1.5%. MRep showed the lowest incidence at 6 
months, 2.06±0.5%, compared with 3.19±1.2% in MVRm and 5.2±1.6% in 
MVRb (no difference between groups were detected during the period 1-6 
months, P=NS). MRep showed also the lowest long term incidence of IS, 
6.08±0.9% at 5 years and 9.9±1.3% at 10 years (1.15±0.1 per 100 patients- 
years), smaller compared with MVRm, respectively 16.1±2.7% and 
23.3±3.5% (2.74±0.4 per 100 patients-years) (P<0.0001), not different from 
MVRb, 8.01±2.1% and 12.2±2.9% respectively (1.65±0.4 per 100 patients-
years)(P=NS) (Actuarial incidence of IS in Figure 1) (Results summarized in 
Table 2) 
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Incidence of ischemic stroke compared with expected 
Comparing incidence of IS observed  with incidence expected in the 
Olmsted County population all the patients during the first postoperative 
month showed a remarkable excess of risk of IS (overall relative risk 40.73): 
as high as 30.94 (P<0.001) after MRep and even more high  after  MVRm , 
43.36 (P<0.001),  and after MVRb, 72.29 (P<0.001). Beyond the first month 
the relative risk strongly decreased in all the groups, but while in MVRm 
still persisted noteworthy excess of risk (RR,  4.77; P<0.001), it normalized 
in MVRb group (RR, 0.98) and the residual excess of risk in the MRep was 
not significant (RR, 1.30 P=0.07). Beyond 6 months MVRm still showed 
increased risk (RR, 4.31, P<0.0001), while in the other groups the risk 
became not different from the risk in the population (RR, 1.17, P=0.302 in 
MRep; RR, 0.90, P=0.729 in MVRb) 
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Predictors of ischemic stroke 
Logistic regression analysis was used to predict IS on the first month after 
surgery and between 1 and 6 months, Cox proportional-hazards modeling 
was used to predict IS after 6 months. 
For those IS during the first postoperative month, at the univariate analysis 
predictors were age, female sex, intra aortic balloon pump (IABP), presence 
of coronary artery disease (CAD), hypertension and MVRb; female sex 
(P=0.047; odds ratio, 2.28; 95%CI 1.01 to 5.38) resulted the only 
independent predictor. For those IS occurring between 1-6 months, 
independent predictors were age (P=0.048; odds ratio/5 years, 1.44; 95%CI 
1.00 to 2.25), hypertension (P=0.027; odds ratio 4.33; 95%CI 1.16 to 20.33) 
and MVRm (P=0.018; odds ratio 6.04; 95%CI 1.38 to 25.24). 
At the univariate analysis predictors of IS occurring beyond 6 months 
resulted age, mechanical prosthesis, combined atrial fibrillation at 
surgery/prior the event and left atrial dimension (LAD) >50 mm; 
independent predictors were age (P=0.006; risk ratio/5 years, 1.14; 95%CI, 
1.03 to 1.26) and MVRm (P<0.001; risk ratio, 3.02; 95%CI, 1.94 to 4.65). 
MRep was an independent favorable predictor of long term survival free 
from ischemic stroke (P=0.002; risk ratio, 0.52; 95%CI, 0.34 to 
0.79).(Results summarized in Table 4-5)  
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Combined IS /TIA: absolute incidence and rates compared with 
expected   
 
Incidence of the combined end point ischemic stroke/TIA was analyzed. 
While during the first month and during the period 1-6 months there was no 
difference between groups regarding the incidence of ischemic stroke/ TIA, 
also for ischemic stroke/TIA MRep presented the lowest long term 
incidence, 10.9±1.1% at 5 years and 16.6±1.7% at 10 years (2.02±0.2 per 
100 patients-years), not different from MVRb, respectively 13.19±2.6% and 
19.1±3.4% (2.58±0.46 per 100 patients-years) (P=NS), smaller compared 
with MVRm, respectively 23.4±3.1% and 32±3.7% (4.09±0.5 per 100 
patients-years) (P<0.0001). (Actuarial incidence of ischemic stroke/TIA in 
Figure 3) (Results summarized in Table 6). 
In comparison to incidence of ischemic stroke/TIA expected in the general 
population, during the first postoperative month all the patients showed an 
important excess of risk (overall relative risk, 42.67), regardless of the type 
of MV surgery. In fact the risk ratio was as high as 38.54 (P<0.001) after 
MRep, 42.61 (P<0.001) after MVRm and 56.92 (P<0.001) after MVRb. 
Beyond 1 month, the relative risk strongly decreased in all the groups but 
still persisted in all of them an excess of  risk, higher in MVRm (RR, 5.37 
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P<0.001), not indifferent in MRep (RR, 1.81 P<0.001) and in MVRb (RR, 
1.57 P=0.035) the MVRb. Beyond 6 months the relative  risk persisted 
lightly increased in the MRep group (RR 1.55, P<0.001) and in the MVRb 
(RR 1.36, P=0.18704), severely increased in MVRm  (RR 4.92, P<0.001) 
(Results summarized in table7). 
 
 
 
ICH and combined IS/ICH: absolute incidence and rates compared with 
expected  
 
Only 10 patients experienced an ICH during the follow up: 1in MRep, 5 in 
the MVRm and 4 in the MVRb and only 1 patient suffered a SAH, in the 
MVRm group. Compared with expected in the general population, only 
patients in MVRm group presented long term excess risk of ICH (RR 3.76, 
P=0.003), while patients with MVRb showed excess risk only in the first 30 
days (RR 55.07, P<0.0001)  (Results summarized in table 8). 
A total of 140 patients experienced the combined end point IS/ICH stroke: 
66 were in MRep group, 49 were in MVRm group and 25 were in MVRb 
group.  
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In comparison to incidence expected in the general population, also for the 
combined end point IS/ICH there was in all the groups an excess of risk 
during the first month, beyond 1 month only the MVRm group showed 
increased risk (RR, 4.87, P<0.0001) (Results summarized in table 9) 
 
 
 
Incidence of total thromboembolic events (ischemic stroke, TIA, 
peripheral and mesenteric embolism).  
Over the entire follow-up a total of 212 patients experienced a TE: most, 
201, experienced a CV-TE, 9 had a peripheral event and 2 had a mesenteric 
event; 114 were in the MRep group, 64 in the MVRm group and 34 were in 
the MVRb group.  
Also for the combined end point total TE MRep presented the lowest long 
term incidence, 11.6±1.1% at 5 years and 17.2±1.7% at 10 years, (2.1±0.2 
per 100 patients-years), smaller compared with MVRm, respectively 
23.8±3.1% and 33.1±3.8% (4.3±0.5 per 100 patients-years) (P<0.001), not 
different from MVRb, respectively 14.9±2.8% and 20.8±3.5%, (2.8±0.5 per 
100 patients-years) (P=NS)(Result summarized in Table 10) 
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Incidence and predictors of Bleeding 
A total of 136 patients experienced a Bleed event over the entire follow up 
(58 in the MRep group, 39 in the MVRm group and 39 in the MVRb group). 
Incidence was high during the first postoperative month, especially in the 
MVRb group (a total of 51events, 18 in the MRep, 11 in the MVRm and 22 
in the MVRb). MRep presented the lowest long term incidence of Bleed, 
1.0±0.1 per 100 patients-years smaller than MVRm, 2.3±0.3 per 100 
patients-years (P<0.001) and MVRb, 3.4±0.5 per 100 patients-years 
(P<0.001), but not different from MVRb when we excluded the 
perioperative Bleed. (0.7±0.1 per 100 patients-years in MRep and 1.5±0.4 
per 100 patients-years in MVRb, P=NS). MVRm showed, compared with 
MRep also after 1 month (1.7 per 100 patients-year) significant increase of 
Bleed risk. The only independent predictor for the postoperative Bleed 
resulted age at surgery (P=0.007; odds ratio/5 years, 1.19; 95%CI, 1.04 to 
1.39), while mechanical prosthesis, age and male gender resulted 
independent predictor of Bleed beyond 6 months. (Incidence and Predictors 
of Bleed are summarized in table 11-12) 
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DISCUSSION 
 
 
The present study, by analyzing a large cohort of patients who underwent 
surgery for MR, by analyzing the time dependence of TE events after 
surgery and by comparing IS rates to those in the general population 
provides a unique view of TE events after surgery for MR. Moreover at our 
knowledge this is the first study in which incidence of IS and any CV events 
observed after cardiac surgery was compared with incidence expected in the 
normal population to demonstrate, removing the confounding factor of 
natural events, any excess of risk directly related to the surgical procedure 
and to the different modalities of MV surgery for MR. The observations in 
the present study are both concerning and encouraging. Indeed, the concerns 
stem from the fact that surgery is associated with excess risk of IS and of the 
combined complication IS-TIA. The encouraging results are related to the 
decline of TE events over time after surgery for MR, so that in patients who 
receive either MRep or MVRb, IS rates are not different long-term from 
those in the general population. Thus, MRep which compared to MVR, 
results in restoration of life expectancy has also the advantage of imposing 
no excess IS risk beyond the 6th post-operative month and is confirmed as 
the preferred mode of surgical correction of MR. Conversely, MVRm is 
 18
associated, in addition to the excess mortality previously noted, with 
sustained risk of IS and bleeding and in that is the least desirable mode of 
correction of MR.  
 
Early Thromboembolic events 
Thrombo-embolic events occurring early after cardiac surgery have been the 
main focus of research, and were addressed mostly in pazients undergoing 
coronary by pass surgery. 1, 3, 5, 6. The focus on early events is justified by 
direct casual link between the operative procedure and the TE event. 
The early postoperative (<30 days) incidence of IS or IS/TIA 1.9% and 2.6% 
are lower than those reported after coronary1, 3, 5, 6 or mitral 3, 18 surgery . This 
lower rate pertains in part to strict definition of IS or TIA by a neurologist15 
but nevertheless is high enough to justify careful attention. Although macro 
embolization is now rare , mechanisms involving thrombotic, fat or gaseous 
micro-emboli from the extracorporeal circulatory system or aortic 
atherosclerotic lesions have been suggested. 19, 20 21 However the risk is not 
only due to the surgical procedure and remains high during the first post-
operative month, resulting approximately 40 times the spontaneous risk of 
stroke in the general population with similar characteristics of age and sex. It 
is well known that prosthetic materials involved in all valve surgeries 
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activate platelets leading to increased platelet deposition 22 and clot 
formation. Thus our results which show that IS rate is high during the first 
post-operative month independently from the procedure performed strongly 
recommend  prevention of thrombus formation in all patients undergoing 
MR surgery. The fact that female sex turned out to be an independent risk 
factor for TE and IS is not well explained, but it is coherent with other 
observations in the literature.9, 23 . 
 
Long-term thrombo-embolic and haemorrhagic complications  
The risk of TE complications in patients with MVRm is well known. 
Although a clinical trial suggested that mechanical mitral prostheses were 
not associated with higher risk of stroke 24, clinical practice studies showed 
high TE rates 2 25. Our long-term large study emphasizes the higher TE and 
IS rates with MVRm than MVRb and MRep. Despite TE and IS risk decline 
over time, an excess risk associated with MVRm is evident beyond 6 
months. However the effective risk  is difficult to estimate since patients 
with MVRm are younger than patients with MVRb. Thus comparison to 
expected rate of IS or IS/TIA is essential by showing that MVRm multiplies 
long-term IS risk by 4 to 5. This excess risk is supported by multivariate 
analysis showing that, adjusting for all the other independent risk factors of 
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IS, MVRm is associated with 3 times higher risk of IS compared with 
MVRb. In addition, since all patients with MVRm are on anticoagulation 
therapy, the rates of bleeding is notable in MVRm, more than 3% per year, 
and in multivariate analysis is 2.5 times higher than with MVRb.  
This combined excess risk in patients with MVRm support the fact to avoid 
this type of procedure if it is possible.  
For both MVRb and MRep we observed, similarly to MVRm, a marked 
decline of the risk of TE and IS after the first postoperative month. Of all the 
procedure MRep was associated with the lowest absolute rates of TE, IS and 
IS/TIA. Such an advantage with MRep has been controversial 26 27 probably 
because its demonstration requires large samples and long-term analysis. 
However, since the group with MVRb and MRep are different in age, 
interpretation of TE rates requires comparison to expected rates. While the 
combined endpoint of IS/TIA occurs at an excess rate with both procedures 
beyond the first post-operative month, underscoring the need for exploring 
further preventive measures, our study provides remarkable results. Indeed, 
the risk of IS, the most frequent and serious TE complication, in MVRb and 
MRep beyond 180 days is similar and compared with expected in the 
general population is not significantly elevated. This very important result 
support the fact that MRep results in long-term restoration not only of life 
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expectancy 28 29 but also of the IS risk. MRep is also remarkable by 
providing the lowest long-term risk of bleeding so that MRep is unique in 
combining long-term morbidity to mortality benefit.  
 
Mechanism of early and long-term TE  
In the present study most part of the TE were noted during the first month. It 
is well known that the events leading to TE start during surgery. In fact, 
although macro embolization is less common during modern cardiac 
surgery, thrombus, lipid or gaseous microemboli can originate from the 
extracorporeal circulatory pump system and from atherosclerotic lesion in 
the ascending aorta manipulated during CABG and heart valve surgery. 30 19 
20
 
31
 
32
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. Particularly heart valve procedures, as Abu-Omar et al reported 33, 
compared with CABG and off-pump CABG, showed higher incidence of 
microemboli detected by transcranial Doppler ultrasound.  In clinical studies 
not always heart valve surgery compared with CABG surgery showed higher 
rate of postoperative IS and TE 34 30 8 35. 
During heart valve surgery the damaged perivalvular tissue and the 
prosthetic materials activate platelets as soon as blood starts flowing across 
the valve, leading to immediate platelet deposition22, 36, 37. A Dacron or 
Teflon sewing ring is common to mechanical and biological prostheses and 
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an annuloplasty ring is almost always used during repair of the MV. Platelet 
deposition on the prosthetic ring start immediately activiting the clotting 
system. At the same time start the process of healing of the MV wounds but 
the exact timing of restoration of the endothelial lining, which represents the 
only one surface resistant to thrombus formation, is not well known.  
Tamura et al 38 found in a study on sheep that, compared with myocardial 
wounds (after MI) and with wounds in other tissues, the healing of MV 
leaflet is a much slower process. In fact it requires 8-12 weeks for the 
formation of a dense collagenous scar and complete restoration of the 
endothelial lining, Possible explanations for this delay in the healing process 
were the low degree of inflammatory cell infiltration compared with normal 
healing process present in other tissue and the lack of newly formed blood 
vessels until 12 weeks. The delay in the MV healing process can at least in 
part explain the persistency of TE in MRep after the early postoperative 
phase. Della Barbera et all 39 studied the histological process after placement 
of a new generation annuloplasty ring in MV position in adult sheep. After 
63-110 days from implantation the ring, surrounded by inflammatory cells 
and neovessels, was fully encapsulate by fibrous tissue and a continuous 
lining of endothelium coated the fibrous tissue surface. But in the study they 
tested a “new” generation annuloplasty ring, coated with Carbofilm, that 
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enhance biocompatibility of the artificial product, then the “old” ring could 
need even more time for a complete encapsulating and endothelization.  
 In the present study patients with MVRb showed high rate of early 
embolization (first month) with complete normalization of the risk of serious 
emboli after 1 month. Biological valves, principally due to the toxic effect of 
pre-operative fixation with glutaraldehyde, show a lack of host endothelial 
cell ingrowth on the valvular surface 40 41 42 that promotes thrombus 
formation explaining the early postoperative high TE rate; nevertheless 
partial in-vivo re-endothelialization has been reported40, 43, 44. 
Emboli after cardiac surgery could be also related to the presence of AF. In 
fact AF, which is associated with embolic event, and stroke in particular, in 
the general population 45-47, is a common complication in the early 
postoperative period. Previous studies reported strong correlation between 
postoperative AF development and incidence of stroke.48In this study the 
presence of AF was a predictor of IS beyond 6 months at the univariate 
analysis (RR, 1.83; 95%CI, 1.22 to 2.74; P=0.003).  
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Is well known that left atrial appendage (LAA)  plays a fundamental role in 
the formation of atrial thrombus and probably in causing IS both in patients 
with AF and sinus rhythm.49-51. 
One suggestive surgical procedure that could be safely52 performed during 
MV surgery to reduce incidence of IS is the ligation of the LAA. Garcia-
Fernandez et all found that LAA ligation during MV surgery reduce the risk 
of late embolism53, but in this study most of the patients had rheumatic valve 
disease and were in AF. Further randomized trials are needed to determine if 
LAA ligation effectively reduces incidence of IS in patients underwent MV 
surgery. 
Another possible source of TE is the presence of AF. In several studies, in 
fact, the Cox-Maze procedure resulted effective to eliminate AF and restore 
sinus rhythm during MV surgery54, 55 reducing incidence of stroke55-58. 
Therefore Cox-Maze procedure should be carefully evaluated in patients in 
AF who undergo MV surgery. 
Atherosclerosis of the ascending aorta is known to be an important risk 
factors for IS and embolization after cardiac surgery32, 59. Since for 
evaluation of ascending aorta epiaortic ultrasonography is superior to 
transesophageal echocardiography and palpation60it should be performed 
during cardiac surgery for the detection and the quantification  of 
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atherosclerosis at this level. Surgical techniques, like changes in the position 
of aortic cannula61, single clamp technique{Grega, 2003 #2051, aortic resection and graft 
replacement62and applying intra-aortic filtration  before aortic cross-
clamping63, showed to reduce systemic and cerebral embolization due to 
ascending aorta atherosclerosis.  
 
Predictors of ischemic stroke 
 
The identification of female sex as an independent risk factor for those IS 
which occur early after surgery is not new8; in another previous study female 
sex was associated to delayed strokes after cardiac surgery23. Age, CAD and 
IABP, which were predictors of early IS in the univariate analysis, appeared 
to be risk factors also in previous studies 1, 5, 23, 59, 64-69. Age, hypertension and 
MVRm, independent predictors of delayed IS, were already found to be 
predictors of IS in other studies23, 64.  
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CONCLUSION 
 
This large study of MR surgery provides observations both concerning 
and encouraging. It is concerning that MR surgery is followed by excess 
risk of TE compared to the general population. Indeed all the modalities 
of MR surgery have a high risk of TE during the first postoperative 
month. It is also concerning that throughout follow-up patients with 
MVRm incur high risk of TE or bleeding. From the other side it is 
encouraging that the risk of TE declines after the high-risk early post-
operative phase and that patient who receive MRep or MVRb incur long-
term TE rates similar to those in the general population.   
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CLINICAL IMPLICATION 
 
In the present study MRep provides, in addition to its low mortality, the 
lowest morbidity and is confirmed to be the preferred mode of surgical 
correction of MR. Conversely, MVRm is associated, in addition to the 
excess mortality previously noted, with sustained risk of TE and bleeding 
and thereby is the least desirable modality of correction of MR. Regarding 
TE and bleeding MVRb showed to be in the present study a good alternative 
to MRep and should be seriously considered whenever MRep is not 
performable.  
To support the guideline recommendation of early MR surgery in 
asymptomatic patients, MRep is an essential condition and clinical trial 
should be designed to minimize the risk of stroke in the first months 
following MR surgery.   
 
 
 
 
 
 
 28
 
 
REFERENCES 
1. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral 
outcomes after coronary bypass surgery. Multicenter Study of Perioperative 
Ischemia Research Group and the Ischemia Research and Education 
Foundation Investigators. N Engl J Med 1996;335(25):1857-63. 
2. Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, 
McGoon DC. Systemic thromboembolism in mitral and aortic Starr-Edwards 
prostheses: a 10-19 year follow-up. Circulation 1982;66(2 Pt 2):I157-61. 
3. Taylor NE, O'Brien S, Edwards FH, Peterson ED, Bridges CR. 
Relationship between race and mortality and morbidity after valve 
replacement surgery. Circulation 2005;111(10):1305-12. 
4. Fuster V, Danielson M, Robb R, Broadbent J, Brown AJ, Elveback L. 
Quantitation of left ventricular myocardial fiber hypertrophy and interstitial 
tissue in human hearts with chronically increased volume and pressure 
overload. Circulation 1977;55:504-8. 
5. Tuman KJ, McCarthy RJ, Najafi H, Ivankovich AD. Differential 
effects of advanced age on neurologic and cardiac risks of coronary artery 
operations. J Thorac Cardiovasc Surg 1992;104(6):1510-7. 
6. Stamou SC, Hill PC, Dangas G, et al. Stroke after coronary artery 
bypass: incidence, predictors, and clinical outcome. Stroke 2001;32(7):1508-
13. 
7. Reed GL, 3rd, Singer DE, Picard EH, DeSanctis RW. Stroke 
following coronary-artery bypass surgery. A case-control estimate of the risk 
from carotid bruits. N Engl J Med 1988;319(19):1246-50. 
 29
8. Hogue CW, Jr., Murphy SF, Schechtman KB, Davila-Roman VG. 
Risk factors for early or delayed stroke after cardiac surgery. Circulation 
1999;100(6):642-7. 
9. Ruel M, Masters RG, Rubens FD, et al. Late incidence and 
determinants of stroke after aortic and mitral valve replacement. Ann Thorac 
Surg 2004;78(1):77-83; discussion -4. 
10. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, 
Enriquez-Sarano M. Burden of valvular heart diseases: a population-based 
study. Lancet 2006;368(9540):1005-11. 
11. Orszulak TA, Schaff HV, Pluth JR, et al. The risk of stroke in the 
early postoperative period following mitral valve replacement. Eur J 
Cardiothorac Surg 1995;9(11):615-9 discuss 20. 
12. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines 
for the management of patients with valvular heart disease: a report of the 
American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines (writing committee to revise the 1998 Guidelines for the 
Management of Patients With Valvular Heart Disease): developed in 
collaboration with the Society of Cardiovascular Anesthesiologists: endorsed 
by the Society for Cardiovascular Angiography and Interventions and the 
Society of Thoracic Surgeons. Circulation 2006;114(5):e84-231. 
13. Avierinos JF, Brown RD, Foley DA, et al. Cerebral ischemic events 
after diagnosis of mitral valve prolapse: a community-based study of 
incidence and predictive factors. Stroke 2003;34(6):1339-44. 
 30
14. Boudoulas H, Vavuranakis M, Wooley CF. Valvular heart disease: the 
influence of changing etiology on nosology. J Heart Valve Dis 
1994;3(5):516-26. 
15. Brown R, Whisnant J, Sicks J, O'Fallon W, Wiebers D. Stroke 
incidence, prevalence, and survival: secular trends in Rochester,  
Minnesota, through 1989. Stroke 1996;27:373-80. 
16. Edmunds LJ, Clark R, Cohn L, Miller D, Weisel R. Guidelines for 
reporting morbidity and mortality after cardiac valvular operations. Ann 
Thorac Surg 1988;46:257-9. 
17. Brown RD, Jr., Petty GW, O'Fallon WM, Wiebers DO, Whisnant JP. 
Incidence of transient ischemic attack in Rochester, Minnesota, 1985-1989. 
Stroke 1998;29(10):2109-13. 
18. Bucerius J, Gummert JF, Borger MA, et al. Stroke after cardiac 
surgery: a risk factor analysis of 16,184 consecutive adult patients. Ann 
Thorac Surg 2003;75(2):472-8. 
19. Davila-Roman VG, Murphy SF, Nickerson NJ, Kouchoukos NT, 
Schechtman KB, Barzilai B. Atherosclerosis of the ascending aorta is an 
independent predictor of long-term neurologic events and mortality. J Am 
Coll Cardiol 1999;33(5):1308-16. 
20. Mackensen GB, Ti LK, Phillips-Bute BG, Mathew JP, Newman MF, 
Grocott HP. Cerebral embolization during cardiac surgery: impact of aortic 
atheroma burden. Br J Anaesth 2003;91(5):656-61. 
21. Mullges W, Franke D, Reents W, Babin-Ebell J. Brain microembolic 
counts during extracorporeal circulation depend on aortic cannula position. 
Ultrasound Med Biol 2001;27(7):933-6. 
 31
22. Chesebro J, Adams P, Fuster V. Antithrombotic therapy in patients 
with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 
1986;8:41-56b. 
23. Doenst T, Ivanov J, Borger MA, David TE, Brister SJ. Sex-specific 
long-term outcomes after combined valve and coronary artery surgery. Ann 
Thorac Surg 2006;81(5):1632-6. 
24. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, 
Rahimtoola SH. Outcomes 15 years after valve replacement with a 
mechanical versus a bioprosthetic valve: final report of the Veterans Affairs 
randomized trial. J Am Coll Cardiol 2000;36(4):1152-8. 
25. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different 
intensities of anticoagulation in patients with prosthetic heart valves. N Engl 
J Med 1990;322(7):428-32. 
26. Akins G, Hilgenberg A, Buckley M, et al. Mitral valve reconstruction 
versus replacement for degenerative or ischemic mitral regurgitation. Ann 
thorac Surg 1994;58:668-76. 
27. Perier P, Deloche A, Chauvaud S, et al. Comparative evaluation of 
mitral valve repair and replacement with Starr, Bjork, and porcine valve 
prostheses. Circulation 1984;70:I187-92. 
28. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. 
Quantitative determinants of the outcome of asymptomatic mitral 
regurgitation. N Engl J Med 2005;352(9):875-83. 
29. Tribouilloy C, Enriquez-Sarano M, Schaff H, et al. Impact Of 
Preoperative Symptoms On Survival After Surgical Correction Of Organic 
 32
Mitral Regurgitation:  Rationale For Optimizing Surgical Indications. 
Circulation 1999;99:400-5. 
30. McKhann GM, Grega MA, Borowicz LM, Jr., Baumgartner WA, 
Selnes OA. Stroke and encephalopathy after cardiac surgery: an update. 
Stroke 2006;37(2):562-71. 
31. Hangler HB, Nagele G, Danzmayr M, et al. Modification of surgical 
technique for ascending aortic atherosclerosis: impact on stroke reduction in 
coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;126(2):391-
400. 
32. Djaiani G, Fedorko L, Borger M, et al. Mild to moderate 
atheromatous disease of the thoracic aorta and new ischemic brain lesions 
after conventional coronary artery bypass graft surgery. Stroke 
2004;35(9):e356-8. 
33. Abu-Omar Y, Balacumaraswami L, Pigott DW, Matthews PM, 
Taggart DP. Solid and gaseous cerebral microembolization during off-pump, 
on-pump, and open cardiac surgery procedures. J Thorac Cardiovasc Surg 
2004;127(6):1759-65. 
34. Salazar JD, Wityk RJ, Grega MA, et al. Stroke after cardiac surgery: 
short- and long-term outcomes. Ann Thorac Surg 2001;72(4):1195-201; 
discussion 201-2. 
35. Kuroda Y, Uchimoto R, Kaieda R, et al. Central nervous system 
complications after cardiac surgery: a comparison between coronary artery 
bypass grafting and valve surgery. Anesth Analg 1993;76(2):222-7. 
36. Dewanjee MK, Trastek VF, Tago M, Kaye MP. Radioisotopic 
techniques for noninvasive detection of platelet deposition in bovine-tissue 
 33
mitral-valve prostheses and in vitro quantification of visceral 
microembolism in dogs. Invest Radiol 1984;19(6):535-42. 
37. Dewanjee MK, Fuster V, Rao SA, Forshaw PL, Kaye MP. 
Noninvasive radioisotopic technique for detection of platelet deposition in 
mitral valve prostheses and quantitation of visceral microembolism in dogs. 
Mayo Clin Proc 1983;58(5):307-14. 
38. Tamura K, Jones M, Yamada I, Ferrans VJ. Wound healing in the 
mitral valve. J Heart Valve Dis 2000;9(1):53-63. 
39. Della Barbera M, Laborde F, Thiene G, et al. Sovering annuloplasty 
rings: experimental pathology in the sheep model. Cardiovasc Pathol 
2005;14(2):96-103. 
40. Ishihara T, Ferrans VJ, Jones M, Boyce SW, Roberts WC. Occurrence 
and significance of endothelial cells in implanted porcine bioprosthetic 
valves. Am J Cardiol 1981;48(3):443-54. 
41. Gendler E, Gendler S, Nimni ME. Toxic reactions evoked by 
glutaraldehyde-fixed pericardium and cardiac valve tissue bioprosthesis. J 
Biomed Mater Res 1984;18(7):727-36. 
42. Speer DP, Chvapil M, Eskelson CD, Ulreich J. Biological effects of 
residual glutaraldehyde in glutaraldehyde-tanned collagen biomaterials. J 
Biomed Mater Res 1980;14(6):753-64. 
43. Zavazava N, Simon A, Sievers HH, Bernhard A, Muller-Ruchholtz 
W. Porcine valves are reendothelialized by human recipient endothelium in 
vivo. J Thorac Cardiovasc Surg 1995;109(4):702-6. 
 34
44. Simon A, Wilhelmi M, Steinhoff G, Harringer W, Brucke P, Haverich 
A. Cardiac valve endothelial cells: relevance in the long-term function of 
biologic valve prostheses. J Thorac Cardiovasc Surg 1998;116(4):609-16. 
45. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. 
Placebo-controlled, randomised trial of warfarin and aspirin for prevention 
of thromboembolic complications in chronic atrial fibrillation. The 
Copenhagen AFASAK study. Lancet 1989;1(8631):175-9. 
46. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an 
independent risk factor for stroke: the Framingham Study. Stroke 
1991;22(8):983-8. 
47. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major 
contributor to stroke in the elderly. The Framingham Study. Arch Intern 
Med 1987;147(9):1561-4. 
48. Lahtinen J, Biancari F, Salmela E, et al. Postoperative atrial 
fibrillation is a major cause of stroke after on-pump coronary artery bypass 
surgery. Ann Thorac Surg 2004;77(4):1241-4. 
49. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, 
function, and role in thromboembolism. Heart 1999;82(5):547-54. 
50. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in 
cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 
1996;61(2):755-9. 
51. Agmon Y, Khandheria BK, Gentile F, Seward JB. Clinical and 
echocardiographic characteristics of patients with left atrial thrombus and 
sinus rhythm: experience in 20 643 consecutive transesophageal 
echocardiographic examinations. Circulation 2002;105(1):27-31. 
 35
52. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion 
Study (LAAOS): results of a randomized controlled pilot study of left atrial 
appendage occlusion during coronary bypass surgery in patients at risk for 
stroke. Am Heart J 2005;150(2):288-93. 
53. Garcia-Fernandez MA, Perez-David E, Quiles J, et al. Role of left 
atrial appendage obliteration in stroke reduction in patients with mitral valve 
prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 
2003;42(7):1253-8. 
54. Handa N, Schaff HV, Morris JJ, Anderson BJ, Kopecky SL, 
Enriquez-Sarano M. Outcome of valve repair and the cox maze procedure 
for mitral regurgitation and associated atrial fibrillation. J Thorac Cardiovasc 
Surg 1999;118(4):628-35. 
55. Kobayashi J, Sasako Y, Bando K, et al. Eight-year experience of 
combined valve repair for mitral regurgitation and maze procedure. J Heart 
Valve Dis 2002;11(2):165-71; discussion 71-2. 
56. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke 
rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 
1999;118(5):833-40. 
57. Bando K, Kobayashi J, Kosakai Y, et al. Impact of Cox maze 
procedure on outcome in patients with atrial fibrillation and mitral valve 
disease. J Thorac Cardiovasc Surg 2002;124(3):575-83. 
58. Ad N, Cox JL. Combined mitral valve surgery and the Maze III 
procedure. Semin Thorac Cardiovasc Surg 2002;14(3):206-9. 
 36
59. Gardner TJ, Horneffer PJ, Manolio TA, et al. Stroke following 
coronary artery bypass grafting: a ten-year study. Ann Thorac Surg 
1985;40(6):574-81. 
60. Bolotin G, Domany Y, de Perini L, et al. Use of intraoperative 
epiaortic ultrasonography to delineate aortic atheroma. Chest 
2005;127(1):60-5. 
61. Borger MA, Taylor RL, Weisel RD, et al. Decreased cerebral emboli 
during distal aortic arch cannulation: a randomized clinical trial. J Thorac 
Cardiovasc Surg 1999;118(4):740-5. 
62. Rokkas CK, Kouchoukos NT. Surgical management of the severely 
atherosclerotic ascending aorta during cardiac operations. Semin Thorac 
Cardiovasc Surg 1998;10(4):240-6. 
63. Christenson JT, Vala DL, Licker M, Sierra J, Kalangos A. Intra-aortic 
filtration: capturing particulate emboli during aortic cross-clamping. Tex 
Heart Inst J 2005;32(4):515-21. 
64. Frye RL, Kronmal R, Schaff HV, Myers WO, Gersh BJ. Stroke in 
coronary artery bypass graft surgery: an analysis of the CASS experience. 
The participants in the Coronary Artery Surgery Study. Int J Cardiol 
1992;36(2):213-21. 
65. Newman MF, Wolman R, Kanchuger M, et al. Multicenter 
preoperative stroke risk index for patients undergoing coronary artery bypass 
graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) 
Research Group. Circulation 1996;94(9 Suppl):II74-80. 
66. Ozatik MA, Gol MK, Fansa I, et al. Risk factors for stroke following 
coronary artery bypass operations. J Card Surg 2005;20(1):52-7. 
 37
67. Almassi GH, Sommers T, Moritz TE, et al. Stroke in cardiac surgical 
patients: determinants and outcome. Ann Thorac Surg 1999;68(2):391-7; 
discussion 7-8. 
68. McKhann GM, Grega MA, Borowicz LM, Jr., et al. Encephalopathy 
and stroke after coronary artery bypass grafting: incidence, consequences, 
and prediction. Arch Neurol 2002;59(9):1422-8. 
69. Ricotta JJ, Faggioli GL, Castilone A, Hassett JM. Risk factors for 
stroke after cardiac surgery: Buffalo Cardiac-Cerebral Study Group. J Vasc 
Surg 1995;21(2):359-63; discussion 64. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 38
Baseline, operative and post-operative characteristics 
 
 
Population 
 
Variables 
Overall MRep MVRm MVRb P 
No of patients 1344 897 231   
Clinical 
characteristics 
    
Age 65±12 65±12 60±11 70±11 <0.0001 
Male sex, % 61 64 62 48 <0.0001 
Hypertension, % 36 37 29 39 0.03 
Diabetes, % 10 8 11 13 0.07 
Creatinine, mg/dl 1.4±0.6 1.4±0.7 1.3±0.6 1.3±0.4 0.92 
Atrial Fibrillation, % 41 37 51 44 0.0006 
NYHA class III-IV, % 57 48 69 78 <0.0001 
Organic MR (%) 81 83 80 69 <0.0001 
Echocardiography 
characteristics 
     
EF ( %) 58±13 59±12 56±14 56±14 0.02 
LVD (mm) 61±9 61±9 61±9 61±9 0.91 
LVS (mm) 39±12 39±13 39±10 39±10 0.97 
LA (mm) 54±10 54±9 54±10 54±11 0.85 
Operative and Post-
operative characteristics 
     
Bypass time 98±48 90±47 110±49 118±50 <0.0001 
CABG (%) 38 38 33 43 0.13 
Coumadin therapy (%) 51 41 95 44 <0.0001 
 
Table 1: Baseline, operative and post-operative characteristics 
NYHA, New York Heart Association; EF, Ejection Fraction;  LVD, Left Ventricle Diastolic diameter; LVS, Left Ventricle systolic diameter; 
LA, Left Atrial; CABG, Coronary Artery Bypass Grafting;   
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Incidence of IS after MV surgery 
 
 
 
 
Figure 1. Plot of incidence of IS in the three groups. Note that MRep and MVRb, compared with MVRm 
present significant lower long term incidence of IS 
IS: ischemic stroke 
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Incidence of IS after MV surgery 
 
Follow up 
 
Over entire follow up 
 
30 days postop 
 
30-180 days postop 
 
Follow up >180 days postop 
Overall 
Events: 130 
5 years incidence=8.09±0.8% 
10 years incidence=12.9±1.2% 
1.52±0.1% patients-years 
Events: 25 
 
30 days incidence=1.92±0.4% 
23.9±4.8% patients-years 
 
Events: 10 
180 days incidence=2.73±0.4% 
Yearly L.R.=2.02±0.6% patients-years 
 
Events: 95 
 
1.19±0.1% patients-years 
MRep 
group 
 
Events: 65 
5 years incidence=6.08±0.9% 
10 years incidence=9.9±1.3% 
1.15±0.1% patients-years 
Events: 13 
30 days incidence=1.47±0.4% 
18.25±5% patients-years 
 
Events: 5 
180 days incidence=2.06±0.5% 
1.46±0.6% patients-years 
 
Events: 47 
0.89±0.1% patients-years 
MVRm 
group 
 
Events: 44 
5 years incidence=16.1±2.7% 
10 years incidence=23.3±3.5 
2.74±0.4% patients-years 
Events: 3 
30 days incidence=1.33±0.8% 
16.6±9.6% patients-years 
 
Events: 4 
180 days incidence=3.19±1.2% 
4.72±2.3% patients-years 
 
Events: 37 
2.46±0.4% patients-years 
MVRb 
group 
 
Events: 21 
5 years incidence=8.01±2.1% 
10 years incidence=12.2±2.9%   
1.65±0.4% patients-years 
Events: 9 
30 days incidence=4.62±1.5% 
59.9±19.9% patients-years 
 
Events: 1 
180 days incidence=5.2±1.6% 
1.49±1.49% patients-years 
 
Events: 11 
0.92±0.3% patients-years 
 
TABLE 2 Incidence of IS during earlythe follow up :  actuarial survival and yearly linearized rate. 
IS: ischemic stroke 
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Figure 2. Risk Ratio (RR) of IS observed compared with expected in the general population    with 
characteristics similar to the population of the study.  
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Incidence of IS after MV surgery: risk ratio compared with expected 
 
 
 
 
 TABLE 3. Risk of IS compared with expected during all the phases of follow 
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Predictors of IS: univariate analysis 
 
                                                                                                                                                                                                     
                                                                  30 days                                                   30-180 days                                                   >180 days                         
Risk factors                          Odds    95%CI          P                           Odds      95%CI        P                        Risk        95%CI              P 
                                             Ratio                                                      Ratio                                                     Ratio 
 
Age/5 years                         1.21  (1.00, 1.50)     0.039                     1.30  (0.96, 1.86)    0.088                      1.09      (1.00, 1.20)      0.041 
 
 
Female sex                          2.43  (1.09,5.63)      0.028 
 
 
CAD                                    2.56  (1.14, 6.10)     0.021 
 
 
IABP                                   2.98  (0.97, 7.53)     0.054 
 
 
MVRb                                 3.02   (1.26, 6.79)     0.014  
  
 
Hypertension                       1.95   (0.88, 4.38)     0.098                     4.39   (1.21, 20.46)   0.023                                                                     
 
 
MVRm                                                                                                3.23   (0.82, 11.4)     0.089                      2.77   (1.81, 4.18)    <0.001   
 
 
LAD>50mm                                                                                                                                                        1.44   (0.96, 2.16)     0.073 
 
 
AF baseline/before IS                                                                                                                                           1.83   (1.22, 2.74)     0.003 
 
 
MRep                                                                                                                                                                    0.50   (0.33, 0.76)     0.001    
 
Table 4.  Predictors of IS during different phases of follow up: univariate analysis. 
CAD:coronary artery disease. IABP: intra aortic balloon pump. LAD; left atrial diameter. IS: ischemic 
stroke 
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Independent predictors of IS 
 
                                                       <30 days                                                   30-180 days                                            >180 days 
Risk factors                          Odds    95%CI        P                              Odds      95%CI         P                            Risk       95%CI         P 
                                             Ratio                                                        Ratio                                                        Ratio 
 
Female sex                           2.28  (1.01, 5.38)    0.047 
 
 
Hypertension                                                                                        4.33   (1.16, 20.33)    0.027 
 
 
MVRm                                                                                                 6.04   (1.38, 25.24)    0.018                      3.02  (1.94, 4.65)   <0.001 
 
 
Age/5 years                                                                                          1.44    (1.00, 2.25)     0.048                      1.14  (1.03, 1.26)    0.006 
 
 
MRep                                                                                                                                                                     0.52  (0.34, 0.79)    0.002    
                                         
 
Table 5. Predictors of IS during different phases of follow up: multivariate analysis. 
IS: ischemic stroke 
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Figure 3. Plot of long term incidence of IS/TIA in the three groups. Note that MRep presents the lowest  
long term incidence of combined end-point IS/TIA, smaller than MVRm (P<0.0001), not different from 
MVRb (P=NS). 
IS: ischemic stroke; TIA: transient ischemic attack 
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Incidence of IS/TIA during the follow up 
 
 
 Over entire follow up 
 
30 days postop 30-180 days postop Follow up >180 days postop 
Overall 
Events: 201 
5 years incidence=13.4±1% 
10 years incidence=19.8±1.4% 
2.49±0.1% patients-years 
Events: 34 
30 days incidence=2.62±0.4% 
32.7±5.6% patients years 
 
Events: 21 
180 days incidence=4.32±0.6% 
4.3±0.9% patients years 
 
Events: 146 
1.95±0.1% patients-years 
MRep 
group 
 
Events: 109 
5 year incidence=10.9±1.1% 
10 years incidence=16.6±1.7% 
2.02±0.2% patients-years 
Events: 21 
30 days incidence=2.39±0.5% 
29.6±6.4%  patients-years 
 
Events: 13 
180 days incidence=3.92±0.6% 
3.85±1.06% patients-years 
 
Events: 75 
1.46±0.16% patients-years 
MVRm 
group 
 
Events: 61 
5 year incidence=23.4±3.1 
10 years incidence=32±3.7% 
4.09±0.5% patients-years 
Events: 4 
30 days incidence=1.78±0.9% 
22.2±11.1% patients-years 
 
Events: 5 
180 days incidence=4.1±1.3% 
5.95±2.6% patients-years 
 
Events: 52 
3.74±0.5% patients-years 
MVRb 
group 
 
Events: 31 
5 year incidence=13.19±2.6% 
10 years incidence=19.1±3.4%    
2.58±0.4% patients-years 
Events: 9 
30 days incidence=4.62±1.5% 
59.9±19.9% patients-years 
 
Events: 3 
180 days incidence=6.3±1.7% 
4.52±2.6% patients-years 
 
Events: 19 
1.69±0.38% patients-years 
 
 
Table 6. Incidence of IS/TIA during the follow up : actuarial survival and yearly linearized rate. 
IS: ischemic stroke; TIA: transient ischemic attack 
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Risk of IS/TIA compared with expected in the general population 
 
 
 
Table 7. Risk of IS/TIA compared with expected during the follow up 
IS: ischemic stroke; TIA: transient ischemic attack 
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Risk of ICH compared with expected in the general population 
 
Period of time after 
MV surgery 
Over entire follow up 
 
30 days Follow up >30 days 30-180 days Follow up >180 days 
Overall 
RR=1.13, (0.54, 2.08) 
P<0.001 
RR=11.79, (0.30, 65.45) 
P=0.001 
RR=1.02, (0.46, 1.93) 
P=0.914 
 
RR=0.00, (0.00, 7.67) 
P=0.478 
 
RR=1.02, (0.47, 1.93) 
P=0.917 
MRep group 
 
RR= 0.17, (0.00, 0.97) 
P=0.040 
 
RR=0.00, (0.00, 64.16) 
P=0.807 
 
RR=0.17, (0.00, 0.97) 
P=0.040 
 
RR=0.00, (0.00, 11.12) 
P=0.556 
 
RR=0.17, (0.00, 0.97) 
P=0.040 
MVRm group 
 
RR=3.76, (1.22, 8.76) 
P=0.003 
RR=0.00, (0.00, 404.2) 
P=0.921 
RR=3.76, (1.22, 8.76) 
P=0.003 
 
RR=0.00, (0.00, 71.37) 
P=0.812 
 
RR=3.77, (1.22, 8.77) 
P=0.002 
MVRb group 
 
RR=2.23, (0.61, 5.70) 
P=0.117 
RR=55.07, (1.39, 305.7) 
P<0.001 
RR=1.67, (0.35, 4.87) 
P=0.404 
 
RR=0.00, (0.00, 37.87) 
P=0.752 
 
RR=1.67, (0.35, 4.87) 
P=0.402 
 
 
Table 8. Risk of ICH compared with expected during the follow up 
ICH: intracranial haemorrhage 
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Risk of IS/ICH compared with expected in the general population 
 
 
Period of time after 
MV surgery 
Over entire follow up 
 
30 days Follow up >30 days 30-180 days Follow up >180 days 
Overall 
RR=2.08, (1.75, 2.46) 
P=0.00000 
RR=38.27, (24.99, 56.07) 
P=0.00000 
RR=1.70, (1.40, 2.04) 
P=0.00000 
 
RR=2.62, (1.26, 4.83) 
P=0.00159 
 
RR=1.55, (1.27, 1.88) 
P=0.00002 
MRep group 
 
RR= 1.49, (1.15, 1.89) 
P= 0.00183 
 
RR=27.95, (14.83, 47.84) 
P=0.00000 
 
RR=1.20, (0.90, 1.56) 
P=0.23733 
 
RR=1.88, (0.61, 4.38) 
P=0.15556 
 
RR=1.08, (0.80, 1.44) 
P=0.65452 
MVRm group 
 
RR=5.19, (3.84, 6.86) 
P=0.00000 
RR=39.38, (8.14, 114.9) 
P=0.00000 
RR=4.87, (3.56, 6.50) 
P=0.00000 
 
RR=9.41, (2.57, 24.12) 
P=0.00000 
 
RR=4.46, (3.21, 6.02) 
P=0.00000 
MVRb group 
 
RR=1.86, (1.21, 2.75) 
P=0.00182 
RR=72.40, (34.72, 133.2) 
P=0.00000 
RR=1.12, (0.63, 1.85) 
P=0.68735 
 
RR=1.38, (0.03, 7.66) 
P=0.72704 
 
RR=1.05, (0.57, 1.76) 
P=0.89006 
 
 
 
 
Table 9. Risk of ischemic/hemorrhagic strokes compared with expected during the follow up 
IS: ischemic stroke; ICH: intracranial haemorrhage 
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 Overall 
1344 pts 
MRep 
897 pts 
MVRm 
231 pts 
MVRb 
216 pts 
 
IS 130 (10%) 65 (7%) 44 (19%) 21 (10%) 
TIA 71 (5%) 44 (5%) 17 (7%) 10 (5%) 
Peripheral/ 
Mesenteric 
TE 
11 (8%) 5 (0.6%) 3 (1%) 3 (1%) 
Total TE 212 (16%) 114 (13) 64 (28%) 34 (16) 
 
Table 10. Distribution of  any TE in the different groups (Overall, MRep, MVRm and MVRb) 
IS: ischemic stroke; TIA: transient ischemic attack 
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Incidence of total TE during the follow up 
 
 
 Over entire follow up 
 
30 days postop 30-180 days postop Follow up >180 days postop 
Overall 
5 years incidence=14.2±1% 
10 years incidence=20.7±1.4% 
Yearly L.R.=2.6±0.2%/y 
30 days incidence=2.85±0.5% 
Yearly L.R.=38.6±5.8%/y 
 
180 days incidence=4.7±0.6% 
Yearly L.R.=4.72±1%/y 
 
Yearly L.R.=2±0.1% per year 
MRep 
group 
 
5 year incidence=11.6±1.1% 
10 year incidence=17.2±1.7 
L.R.=2.1±0.2% per year 
30 days incidence=2.5±0.5% 
L.R.=31.05±6.6% per year 
 
180 days incidence=4.15±0.7% 
L.R.=4.15±1.1% per year L.R.=1.57±0.17% per year 
MVRm 
group 
 
5 year incidence=23.8±3.1 
10 year incidence=33.1±3.8 
L.R.=4.3±0.5% per year 
30 days incidence=1.78±0.9% 
L.R.=22.17±11.1% per year 
 
180 days incidence=4.56±1.4% 
L.R.=7.14±2.9% per year L.R.=3.91±0.5% per year 
MVRb 
group 
 
5 year incidence=14.9±2.8% 
10 year incidence=20.8±3.5% 
L.R.=2.8±0.5% per year 
30 days incidence=5.67±1.6% 
L.R.=73.49±22.15% per year 
 
180 days incidence=7.39±1.9% 
L.R.=4.54±2.6% per year L.R.=1.78±0.4% per year 
 
TABLE 11 Incidence of total thromboembolic events the follow-up:  actuarial survival and yearly 
linearized rate. 
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Incidence of Bleeding events during the follow up 
 
 Over entire follow up 
 
30 days postop 30-180 days postop Follow up >180 days postop 
Overall 
5 years incidence=8.6±0.8% 
10 years incidence=13.7±1.3% 
Yearly L.R.=1.6±0.1% per year 
30 days incidence=3.9±0.5% 
Yearly L.R.=49.5±6.9% per year 
 
180 days incidence=4.6±0.6% 
Yearly L.R.=1.84±0.6% per year 
 
Yearly L.R.=0.96±0.1% per year 
MRep 
group 
 
5 year incidence=6.2±0.9% 
10 year incidence=8.6±1.2% 
L.R.=1.0±0.1% per year 
30 days incidence=2±0.5% 
L.R.=25.3±6% per year 
 
180 days incidence=2.6±0.5% 
L.R.=1.5±0.6% per year L.R.=0.7±0.1% per year 
MVRm 
group 
 
5 year incidence=12.3±2.3 
10 year incidence=20.5±3.3 
L.R.=2.3±0.3% per year 
30 days incidence=4.9±1.4% 
L.R.=62.5±19% per year 
 
180 days incidence=5.8±1.6% 
L.R.=2.4±1.7% per year L.R.=1.7±0.3% per year 
MVRb 
group 
 
5 year incidence=15.2±2.6% 
10 year incidence=25.2±4.1% 
L.R.=3.4±0.5% per year 
30 days incidence=10.8±2.2% 
L.R.=154±33% per year 
 
180 days incidence=12±2.3% 
L.R.=3.1±2.2% per year L.R.=1.4±0.4% per year 
 
TABLE 12 Incidence of total thromboembolic events during the follow-up: actuarial survival and yearly 
linearized rate. 
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Indipendent predictors of Bleeding events  
 
                                                       <30 days                                                   30-180 days                                            >180 days 
Risk factors                          Odds    95%CI        P                              Odds       95%CI          P                         Risk       95%CI         P 
                                             Ratio                                                        Ratio                                                       Ratio 
 
Age/5 years                          1.03   (1.04, 1.39)   0.007                         1.35     (1.01, 1.92)    0.039                  1.14  (1.02, 1.27)    0.010 
 
 
Male sex                                                                                                                                                              1.65   (1.04, 2.71)   0.031 
 
 
MVRm                                                                                                                                                                2.46   (1.52, 3.91)  < 0.001 
 
 
MRep                                                                                                                                                                   0.39  (0.25, 0.61)   < 0.001 
                                         
 
Table 13. Predictors of Bleeding events during the follow up: multivariate analysis 
 
 
 
 
 
